Don't Buy Summit Therapeutics Until This Big Thing Happen

Summit Therapeutics plans to file a Biologics License Application (BLA) in Q4 2025 for ivonescimab plus chemotherapy in second-line NSCLC despite the Harmoni phase 3 study failing to meet a statistically significant overall survival (OS) endpoint and prior FDA guidance that an OS benefit is required. Management disclosed on Oct. 20, 2025 that it will proceed with the filing and believes remaining safety and efficacy data could persuade the FDA; the agency then has 60 days to accept or reject the BLA, creating a binary catalyst for the stock. A BLA acceptance would be a material positive but not a guarantee of approval, while rejection would not be terminal given an expected Harmoni-3 readout in H2 2026 that could support a subsequent filing.

Analysis

Market structure: A BLA acceptance/rejection is binary and idiosyncratic: winners would be competitors with approved second‑line NSCLC regimens and big pharmas that can pressure payors on pricing; losers are Summit (SMMT) and partner Akeso. Even if accepted, expect limited pricing power—initial market share likely single‑digit vs. incumbent IO/chemo combos and an addressable US 2L NSCLC market roughly $0.5–1.5B, constraining revenue upside and valuation uplift to be event‑driven not structural.

Risk assessment: Tail risks include FDA accepting filing but denying approval (regulatory whipsaw), an advisory committee recommending against approval, or a forced capital raise causing >20–40% dilution within 12 months. Time windows: immediate (0–60 days post filing: acceptance decision), short (3–9 months: potential briefing/approval path), long (H2 2026: Harmoni‑3 readout could reopen pathway). Hidden dependency: data integrity and subgroup signals from Akeso’s Harmoni dataset drive FDA sentiment—outsized impact if Akeso revises analyses or faces inspection findings.

Trade implications: Favor defined‑risk directional/volatility trades around the acceptance window. Tactical: small size short via put spreads ahead of BLA submission and the 60‑day window (target 1–2% portfolio risk), switching to long call spreads only after a confirmed acceptance AND visible labeling/review timeline. Pair trade: short SMMT vs long IBB (or biotech basket) to isolate company risk; shift cash from small‑cap biotech into large‑cap pharma/healthcare staples to reduce idiosyncratic drawdown.

Contrarian angles: Consensus underrates probability the FDA will accept the filing for review (not approval) to allow discussion—acceptance probability nearer 25–35% vs. market pricing implying lower; acceptance could produce a >100% squeeze if paired with positive messaging. Conversely, market may be underestimating the ability of negative OS data to force restrictive labeling or require a confirmatory trial (making the post‑acceptance upside much smaller). Expect outsized moves and liquidity stress in SMMT options and small‑cap biotech credit spreads on either outcome.

Key Decisions for Investors

• Establish a defined‑risk short on SMMT sized 1–2% of portfolio using a put‑spread expiring March 2026 (buy ~0.8 delta put, sell further OTM put) ahead of the expected Q4 2025 BLA submission to capture downside from a likely rejection or conservative FDA stance.
• If the FDA issues an acceptance letter (within ~60 days post‑filing), immediately trim/close >50% of the short and initiate a capped upside trade: buy a Jan 2027 call spread sized 1–3% of portfolio to play approval momentum while limiting cash outlay.
• Execute a relative value pair: short SMMT (equity or long puts) vs long IBB (equal dollar) to neutralize sector beta; rebalance on acceptance/rejection events and reduce pair notional if SMMT moves >40% intraday to avoid gamma risk.
• Do not add material long SMMT exposure until either (a) FDA accepts BLA and publishes a favorable review timeline and label expectation, or (b) Harmoni‑3 top‑line in H2 2026 shows statistically significant OS benefit; consider buying 6–12 month call spreads only after those triggers with position size capped at 2–5%.
• Monitor three specific data points over next 60–270 days: the FDA acceptance/rejection letter (time‑stamp is trigger), any FDA briefing/complete response details for labeling requirements, and Akeso’s planned Harmoni‑3 H2 2026 topline—treat each as a discrete re‑rate event and adjust sizing if probability shifts by >15 percentage points.